Compared to Estimates, Integra (IART) Q1 Earnings: A Look at Key Metrics

Integra LifeSciences (IART) reported $382.65 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 3.7%. EPS of $0.41 for the same period compares to $0.55 a year ago.

The reported revenue represents a surprise of +0.13% over the Zacks Consensus Estimate of $382.17 million. With the consensus EPS estimate being $0.43, the EPS surprise was -4.65%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Organic Revenue Growth: -3.5% compared to the -4.5% average estimate based on four analysts.
• Revenue- Codman Specialty Surgical- Total: $280.66 million versus $273 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.
• Revenue- Tissue Technologies- Total: $101.99 million versus $108.60 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -9.3% change.
• Revenue- Tissue Technologies- Wound Reconstruction and Care: $74.78 million versus the two-analyst average estimate of $79.29 million. The reported number represents a year-over-year change of -7.5%.
• Revenue- Tissue Technologies- Private Label: $27.21 million versus the two-analyst average estimate of $26.45 million. The reported number represents a year-over-year change of -13.8%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research